Group 1 - The core viewpoint of the news is that Tonghua Jinma has shown significant stock performance and financial growth, with a notable increase in share price and market capitalization [1][2]. - As of September 30, Tonghua Jinma's stock price increased by 64.46% year-to-date, with a market capitalization of 24.955 billion yuan [1]. - The company has experienced a net inflow of main funds amounting to 4.2117 million yuan, with significant buying activity from large orders [1]. Group 2 - Tonghua Jinma's main business revenue composition includes 59.27% from biochemical drugs, 40.56% from traditional Chinese medicine, and minimal contributions from raw materials and others [1]. - For the first half of 2025, Tonghua Jinma reported an operating income of 650 million yuan, reflecting a year-on-year growth of 0.12%, and a net profit attributable to shareholders of 16.804 million yuan, up 34.77% [2]. - The company has not distributed dividends in the last three years, with a total payout of 210 million yuan since its A-share listing [3].

证券代码：000766 证券简称：通化金马 公告编号：2025-35 通化金马药业集团股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会无否决提案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： 现场会议召开时间为：2025年9月15日下午14:30 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年9月15日9:15—9:25，9:30—11:30和13:00—15:00；通过互联网投票系统 进行网络投票的具体时间为2025年9月15日上午9:15至下午15:00期间的任意时 间。 2、召开地点：吉林省通化市二道江区金马路999号，公司七楼会议室。 出席会议的股东及股东代表共317人，代表股份207,546,714股，占公司股份 总数的21.4742%。 其中：出席现场会议的股东及股东授权委托代表共9人，代表股份 200,010,900股，占公司股份总数的20.6945%。 3、召开方式：采用现场表决与网络投 ...

吉林秉责律师事务所 关于通化金马药业集团股份有限公司 2025 年第三次临时股东会的法律意见书 致：通化金马药业集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）和《通化金马药业集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，吉林秉责律师事务所（以下简称"本所"）接受了通化金马药业集 团股份有限公司（以下简称"公司"）的委托，担任公司 2025 年第三次临时股东 会（以下简称"本次股东会"）特聘专项法律顾问并出具法律意见书。 本次股东会由公司董事会召集，会议召开方式为现场投票与网络投票相结合 的方式。 现场会议的召开时间：2025 年 9 月 15 日下午 14 点 30 分，会议地点为吉林 省通化市通化金马药业集团股份有限公司七楼会议室。 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 15 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过互联网投票 系统进行网络投票的具体时间为 2025 ...

Group 1 - The core viewpoint of the news is the performance and financial metrics of Tonghua Jinma Pharmaceutical Group Co., Ltd, highlighting its stock price increase and market capitalization [1] - As of September 11, Tonghua Jinma's stock rose by 5.03%, reaching a price of 26.29 yuan per share, with a trading volume of 1.584 billion yuan and a turnover rate of 6.61%, resulting in a total market value of 25.409 billion yuan [1] - The company, established on February 26, 1993, and listed on April 30, 1997, focuses on the research, production, and sales of pharmaceuticals, with its main revenue sources being biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 2 - From the perspective of fund holdings, Guolian An Fund has a significant position in Tonghua Jinma, with its Guolian An CSI Pharmaceutical 100A fund holding 96,800 shares, accounting for 1.04% of the fund's net value [2] - The fund reduced its holdings by 47,600 shares in the second quarter, and the estimated floating profit from this investment is approximately 122,000 yuan [2] - The Guolian An CSI Pharmaceutical 100A fund, established on August 21, 2013, has a current scale of 178 million yuan, with a year-to-date return of 20.34% and a one-year return of 38.85% [2]

Core Viewpoint - Tonghua Golden Horse experienced a significant increase of 7.55% in stock price, with a trading volume of 1.863 billion yuan and a fluctuation of 16.29% on the day [2]. Trading Activity - The stock had a turnover rate of 7.68%, with institutional investors net selling 8.3439 million yuan and the Shenzhen Stock Connect net selling 18.0141 million yuan [2]. - The top five trading departments accounted for a total transaction of 9.47 billion yuan, with a net buying amount of 1.42 billion yuan [2]. - Specific trading details show that one institutional seat was involved, with a net sell of 834.39 million yuan, while the Shenzhen Stock Connect was the fourth largest buyer and second largest seller [2][3]. Fund Flow - The stock saw a net inflow of 82.5477 million yuan from major funds, with large orders contributing 74.5637 million yuan to this inflow [2]. - Over the past five days, the net inflow of major funds totaled 89.0080 million yuan [2]. Margin Trading Data - As of September 10, the margin trading balance for the stock was 1.655 billion yuan, with a financing balance of 1.648 billion yuan and a securities lending balance of 6.9283 million yuan [3]. - In the last five days, the financing balance increased by 19.5143 million yuan, representing a growth of 1.20%, while the securities lending balance rose by 871,700 yuan, marking a 14.39% increase [3].

Core Viewpoint - Tonghua Jinma's stock price has shown a significant increase of 54.01% year-to-date, despite a recent decline in the last five trading days [1][2]. Company Overview - Tonghua Jinma Pharmaceutical Group Co., Ltd. is located in Tonghua City, Jilin Province, and was established on February 26, 1993. It was listed on April 30, 1997. The company focuses on the research, production, and sales of pharmaceuticals, with 100% of its revenue derived from the pharmaceutical industry [1]. Financial Performance - For the first half of 2025, Tonghua Jinma achieved an operating income of 650 million yuan, representing a year-on-year growth of 0.12%. The net profit attributable to shareholders was 16.80 million yuan, showing a significant increase of 34.77% compared to the previous year [2]. Stock Performance - As of September 1, the stock price was 24.18 yuan per share, with a market capitalization of 23.37 billion yuan. The trading volume was 230 million yuan, with a turnover rate of 0.99% [1]. - The stock has experienced a net outflow of 6.69 million yuan from main funds, with large orders accounting for 30.51% of total buying and 29.38% of total selling [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 39,500, a rise of 6.54%. The average number of circulating shares per person decreased by 6.13% to 24,457 shares [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings noted [3]. Dividend Information - Since its A-share listing, Tonghua Jinma has distributed a total of 210 million yuan in dividends, with no dividends paid in the last three years [3].

Group 1 - The company announced it will provide a guarantee for a loan application by its wholly-owned subsidiary, Harbin Shengtai Biopharmaceutical Co., Ltd., to Yingkou Bank, with a guarantee amount not exceeding RMB 157,000 million for principal and related interest and fees [1] - The guarantee period is set for three years [1] - After this guarantee, the total external guarantee balance for the company and its subsidiaries will amount to RMB 327,500 million, which represents 145.21% of the company's audited net assets for the year 2024 [1]

通化金马药业集团股份有限公司 突发事件处理制度 （经 2025 年 8 月 28 日公司召开的第十一届董事会 2025 年第七次临时会议审议通过） 第一章 总则 第一条 为提高通化金马药业集团股份有限公司（以下简称"公司"）处置突 发事件的能力，最大限度地预防和减少突发事件及其造成的损害，维护公司正常 的生产经营秩序，根据《公司法》《证券法》《深圳证券交易所股票上市规则》等 有关法律法规和规范性文件的要求以及《通化金马药业集团股份有限公司章程》 （以下简称"《公司章程》"）《信息披露管理制度》的规定，结合公司实际情况， 特制订本制度。 第二条 本制度所称突发事件是指突然发生的、有别于日常经营的、已经或 可能会对公司的经营、财务状况以及对公司的声誉、股价产生严重影响的、需要 采取应急处置措施予以应对的偶发性事件。 第三条 公司应对突发事件工作实行预防为主、预防与应急相结合的原则。 第四条 本制度适用于公司、公司各职能部门、各全资、控股子公司遭遇突 发事件时的处理。 第二章 突发事件范围 第五条 按照社会危害程度、影响范围等因素，突发事件主要包括但不限于： （一）公司大股东出现重大风险，对公司造成重大影响； （二 ...

董事会审计委员会工作细则 （经 2025 年 8 月 28 日公司召开的第十一届董事会 2025 年第七次临时会议审议通过） 通化金马药业集团股份有限公司 第一章 总则 第五条 审计委员会委员由董事长、二分之一以上独立董事或全体董事的三 分之一以上提名，由董事会选举产生。 第六条 审计委员会委员任期与同届董事会董事的任期一致。审计委员会委 员任期届满前，除非出现《公司法》《公司章程》或本制度规定的不得任职之情 形，不得被无故解除职务。 第一条 为强化通化金马药业集团股份有限公司（以下简称"公司"）董事会 决策功能，做到事前审计、专业审计，确保董事会对经营管理层的有效监督，完 善公司治理结构，根据《中华人民共和国公司法》《上市公司治理准则》《上市公 司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件（以下统称"法 律法规"），以及《通化金马药业集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，制订本制度。 第二条 审计委员会根据《公司章程》和本制度规定的职责范围履行职责， 独立工作，不受公司其他部门干涉。 第二章 人 ...

通化金马药业集团股份有限公司 投资者关系管理制度 第四条 投资者关系管理工作应体现公平、公正、公开原则，平等对待全体 投资者，保障所有投资者享有知情权及其它合法权益。 （经 2025 年 8 月 28 日公司召开的第十一届董事会 2025 年第七次临时会议审议通过） 第一章 总则 第五条 除非得到明确授权并经过培训，公司董事、高级管理人员和员工应 避免在投资者关系活动中代表公司发言。 第二章 投资者关系的目的、原则和内容 第六条 投资者关系管理工作的目的是： （一）促进公司与投资者之间的良性关系，增进投资者对公司的进一步了解 和熟悉。 第一条 为进一步完善通化金马药业集团股份有限公司（以下简称"公司"） 治理结构，规范公司投资者关系工作，加强公司与投资者和潜在投资者（以下统 称"投资者"）之间的沟通，加深投资者对公司的了解和认同，促进公司和投资 者之间长期、稳定的良好关系，提升公司的诚信度、核心竞争能力和持续发展能 力，实现公司价值最大化和股东利益最大化，根据《中华人民共和国公司法》（以 下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、中国 证券监督管理委员会（以下简称"中国证监会" ...